Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3693-8448
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.04 million
Profitability
Miscellaneous
Employees17
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions
What is Galmed Pharmaceuticals' stock symbol?
Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."
How were Galmed Pharmaceuticals' earnings last quarter?
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) issued its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.06. Galmed Pharmaceuticals had a negative return on equity of 13.92% and a negative net margin of 423.62%. View Galmed Pharmaceuticals' Earnings History.
When is Galmed Pharmaceuticals' next earnings date?
What price target have analysts set for GLMD?
7 brokers have issued 1 year price targets for Galmed Pharmaceuticals' stock. Their forecasts range from $20.00 to $59.00. On average, they expect Galmed Pharmaceuticals' share price to reach $35.75 in the next twelve months. This suggests a possible upside of 335.4% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.
What is the consensus analysts' recommendation for Galmed Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.
What are Wall Street analysts saying about Galmed Pharmaceuticals stock?
Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "We value ADMA via discounted cash flow (DCF)- based analysis, which models four principal lines of business (Nabi- HB, plasma reselling from ADMA’s own plasma center, BIVIGAM and RI-002). We apply a 10% discount rate and 30% effective tax rate, along with a 2.5% terminal growth rate." (3/14/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $59 12-month PT on Galmed Pharmaceuticals following earnings from 4Q18/2018. The company announced plans to have an end-of-Phase 2b meeting with the FDA during March, with the goal of initiating the Phase 3 ARMOR study in late-2Q19/early-3Q19. Minutes from this meeting and finalized Phase 3 trial design plans could be important data points in 2019. Additionally, Galmed will present a poster on Aramchol improvement in liver glucose homeostasis in NASH at EASL on 4/13 (link)." (3/13/2019)
- 3. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (2/28/2019)
Has Galmed Pharmaceuticals been receiving favorable news coverage?
Media headlines about GLMD stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Galmed Pharmaceuticals' key competitors?
Some companies that are related to Galmed Pharmaceuticals include Vital Therapies (VTL), G1 Therapeutics (GTHX), Intra-Cellular Therapies (ITCI), Eagle Pharmaceuticals (EGRX), ZIOPHARM Oncology (ZIOP), Obseva (OBSV), Vectura Group (VEGPF), Stemline Therapeutics (STML), DiaMedica Therapeutics (DMCAF), Lexicon Pharmaceuticals (LXRX), Odonate Therapeutics (ODT), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA) and Revance Therapeutics (RVNC).
What other stocks do shareholders of Galmed Pharmaceuticals own?
Who are Galmed Pharmaceuticals' key executives?
Galmed Pharmaceuticals' management team includes the folowing people:
- Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
- Mr. Yohai Stenzler, CFO & Controller (Age 36)
- Mr. Guy Nehemya, Chief Operating Officer (Age 34)
- Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
- Dr. Tali Gorfine, Chief Medical Officer (Age 49)
How do I buy shares of Galmed Pharmaceuticals?
Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Galmed Pharmaceuticals' stock price today?
One share of GLMD stock can currently be purchased for approximately $8.21.
How big of a company is Galmed Pharmaceuticals?
Galmed Pharmaceuticals has a market capitalization of $172.56 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.
What is Galmed Pharmaceuticals' official website?
How can I contact Galmed Pharmaceuticals?
Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.
MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
